Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Nvs    crawled time : 06:03    save search
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Published: 2021-03-09 (Crawled : 06:03) - globenewswire.com
NVS | $92.99 -1.5% 990K twitter stocktwits trandingview |
Health Technology
 | | O: 0.14% H: 0.76% C: -0.37%
treatment lung cancer therapy cancer ev
Novartis announces change to the Executive Committee
Published: 2021-03-05 (Crawled : 06:03) - globenewswire.com
NVS | $92.99 -1.5% 990K twitter stocktwits trandingview |
Health Technology
 | | O: -0.17% H: 1.06% C: 0.78%
Gainers vs Losers
51% 49%

Top 10 Gainers
WISA 4 | $5.33 204.57% 190M twitter stocktwits trandingview |
Electronic Technology
SXTC | $1.78 52.14% 33M twitter stocktwits trandingview |
Health Technology
JAGX | $0.1771 49.07% 540M twitter stocktwits trandingview |
Health Technology
DYNT | $0.531 43.36% 30.24% 22M twitter stocktwits trandingview |
Health Technology
MCBC | $13.74 38.37% 1.6M twitter stocktwits trandingview |
Finance
BSGM | $1.52 38.18% 3.2M twitter stocktwits trandingview |
Health Technology
VIAO | $0.2426 -21.23% 230K twitter stocktwits trandingview |
Electronic Technology
KULR | $0.47 -19.27% 6.4M twitter stocktwits trandingview |
Manufacturing
FNCH | $2.98 32.74% 400K twitter stocktwits trandingview |
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.